Rain Oncology IncChange company Symbol lookupSelect an option...RAIN Rain Oncology IncSYBX Synlogic IncNEOV NeoVolta IncFIISO Financial Institutions IncKA Kineta IncTCS Container Store Group IncMLGO MicroAlgo IncINDI indie Semiconductor IncJCI Johnson Controls International PLCFPAY FlexShopper IncGo
Change company Symbol lookup
Select an option...
RAIN Rain Oncology Inc
SYBX Synlogic Inc
NEOV NeoVolta Inc
FIISO Financial Institutions Inc
KA Kineta Inc
TCS Container Store Group Inc
MLGO MicroAlgo Inc
INDI indie Semiconductor Inc
JCI Johnson Controls International PLC
FPAY FlexShopper Inc
Health Care : Pharmaceuticals | Small Cap Value
Company profileRain Oncology Inc. is a late-stage precision oncology company. The Company is focused on developing therapies that target oncogenic drivers to genetically select patients. Its product candidate includes milademetan. Milademetan is an oral, small molecule inhibitor of the p53-mouse double minute 2 (p53-MDM2) complex that reactivates p53. The product candidate is being developed in patients with MDM2-dependent cancers. p53 acts as a regulator of various cellular processes. The activity of p53 is controlled and regulated by the inhibitory protein MDM2. MDM2 binds to p53, thereby inducing degradation and allowing normal cells to function properly. Milademetan, by binding MDM2 at the p53 interaction site, prevents the formation of the MDM2-p53 complex, allowing p53 reactivation and subsequent transcription of genes that trigger cancer cell cycle arrest or apoptosis and can be readily measured by increases in the pharmacodynamic marker MIC-1 (GDF15) in the blood.
|
|
|
|
| |
| Latest Earnings (Q2 ending 06/2023) | Upcoming Announcement (Q3 ending 09/2023) | ||||||
|---|---|---|---|---|---|---|---|
| Q2 Non-GAAP earnings GAAP vs. Non-GAAP EarningsTD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. | -$0.61 | Estimate increased in year leading up to announcement | 1.05% | Q3 consensus estimate | -$0.27 | Q3 consensus estimate is higher than previous yr's Q3 actual | 59.71% |
| Q2 Consensus estimate | -$0.51 | Previous year's Q3 actual | -$0.68 | ||||
Quarterly Consensus Estimate Trends over Time
RAIN's fiscal year ends in December
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.
Information provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.